If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

The long-term research interest in Dr. Shengyu Yang’s lab is to understand the mechanisms underlying cancer metastasis and developing novel therapeutic strategies in the prevention and treatment of cancer metastasis.

The research in the lab currently focus on two areas related to mitochondrial signaling and metabolism in cancer metastasis.

The first area of research effort is to understand how the actin cytoskeleton remodeling in lung adenocarcinoma promotes metastatic colonization by controlling mitochondrial DNA homeostasis and augmenting mitochondrial oxidative phosphorylation. The second area of research effort is to understand the role of mitochondrial calcium signaling in the control of metabolic stress resistance by activating the Keap1-Nrf2 antioxidant response program in metastatic pancreatic cancer.

Teaching and educational interests

Dr. Shengyu Yang is co-directing a new course for medical students at Penn State College of Medicine, Mitochondria in Physiology and Diseases, with Dr. Katherine Aird.

Dr. Yang also lectures on receptor tyrosine kinase signaling, cancer metastasis and mitochondrial dynamics to graduate students.

Education/Academic qualification

Postdoctoral Fellowship, Weill Cornell Medical College

… → 2010

Biophysics, PhD, Chinese Academy of Science

… → 2001

BS, Xiamen University

… → 1996

Fingerprint Dive into the research topics where Shengyu Yang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Research Output

    • 1531 Citations
    • 18 h-Index
    • 43 Article
    • 3 Chapter
    • 1 Comment/debate

    IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer

    Zhao, T., Jin, F., Xiao, D., Wang, H., Huang, C., Wang, X., Gao, S., Liu, J., Yang, S. & Hao, J., Jan 1 2020, In : Theranostics. 10, 9, p. 4088-4100 13 p.

    Research output: Contribution to journalArticle

    Open Access
  • PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

    Wang, X., Li, X., Wei, X., Jiang, H., Lan, C., Yang, S., Wang, H., Yang, Y., Tian, C., Xu, Z., Zhang, J., Hao, J. & Ren, H., Dec 1 2020, In : Signal Transduction and Targeted Therapy. 5, 1, 38.

    Research output: Contribution to journalArticle

    Open Access
  • Fascin Controls Metastatic Colonization and Mitochondrial Oxidative Phosphorylation by Remodeling Mitochondrial Actin Filaments

    Lin, S., Huang, C., Gunda, V., Sun, J., Chellappan, S. P., Li, Z., Izumi, V., Fang, B., Koomen, J., Singh, P. K., Hao, J. & Yang, S., Sep 10 2019, In : Cell Reports. 28, 11, p. 2824-2836.e8

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations

    Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC

    Alhothali, M., Mathew, M., Iyer, G., Lawrence, H. R., Yang, S., Chellappan, S. & Padmanabhan, J., May 16 2019, In : International journal of molecular sciences. 20, 10

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Imaging elemental events of store-operated Ca2+ entry in invading cancer cells with plasmalemmal targeted sensors

    Lu, F., Sun, J., Zheng, Q., Li, J., Hu, Y., Yu, P., He, H., Zhao, Y., Wang, X., Yang, S. & Cheng, H., Mar 1 2019, In : Journal of Cell Science. 132, 6, 224923.

    Research output: Contribution to journalArticle

    Open Access
  • 2 Scopus citations